A phase II trial of DA-125, a novel anthracycline, in advanced non- small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 6, 1999, Pages 518-521

  Kang, Y K ^a   Ryoo, B Y ^a   Kim, T Y ^a   Im, Y H ^a   Kim, B S ^a   Park, Y H ^a   Lee, C T ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Chemotherapy; DA 125; Non small cell lung cancer; Phase II

Indexed keywords

ALKALINE PHOSPHATASE; ANTHRACYCLINE DERIVATIVE; GALARUBICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DOXORUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 0032708908     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051127     Document Type: Article

References (11)

1. 1. Baik NG, Ahn BO, Lee SB, Kim WB, Yang J, Watanabe T (1993) A study on cardiotoxicity of DA-125, a new anticancer antibiotic. J Appl Pharmacol 1: 9-19
2. 2. Cha SW, Park JI, Jeong TC, Shin HC, Ha CS, Kim HC, Yang JI, Han SS, Roh JK (1996) Toxicity studies of DA-125, an anthracycline antitumor antibiotic: intravenous repeated doses for 26 weeks in beagle dogs. J Appl Pharmacol 4: 127-137
3. 3. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151
4. 4. Ginsberg RJ, Vokes EE, Raben A (1997) Non-small cell lung cancer. In: Devita VT Jr, Hellmann S, Rosenberg SA (eds) Cancer: principles and practice of oncology, vol 2, 5th edn. Lippincott-Raven, Philadelphia New York, pp 858-911
5. 5. Hong WS, Jung HY, Yang SK, Kim HR, Min YI (1997) Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin. Anticancer Res 17(5A): 3613-3616
6. 6. Lee MG, Yang J (1996) DA-125. Drugs Fut 21: 782-786
7. 7. Lee SD, Park JB, Lee WI, Shim HJ, Lee ED, Lee JJ, Kim WB, Yang J, Kim CK, Lee MG (1995) Pharmacokinetics and antitumour activity of a new anthracycline, DA-125, after intravenous administration to subcutaneously implanted Lewis-lung-carcinoma-bearing mice. Biopharm Drug Dispos 16(6): 489-505
8. 8. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1): 207-214
9. 9. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: A metaanalysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909
10. 10. Park JB, Ahn BO, Kim WB, Yang JI, Kim SJ, Park JG, Roh JK (1994) Preclinical antitumor activity of DA-125, a new anthracycline derivative: Comparative study with doxorubicin (DXR). Proc Am Assoc Cancer Res 35: 410
11. 11. Roh JK, Rha SY, Lee CI, Lee KH, Lee JJ, Shim HJ, Lee SD, Kim WB, Yang J, Kim SH, Lee MG (1998) Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study. Int J Clin Pharmacol Ther 36(6): 312-319